Equities research analysts predict that Qiagen N.V. (NASDAQ:QGEN) will report $392.98 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Qiagen N.V.’s earnings, with the highest sales estimate coming in at $396.00 million and the lowest estimate coming in at $389.96 million. Qiagen N.V. reported sales of $366.50 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 7.2%. The business is expected to issue its next earnings results on Wednesday, February 7th.
According to Zacks, analysts expect that Qiagen N.V. will report full year sales of $392.98 million for the current year, with estimates ranging from $1.40 billion to $1.43 billion. For the next fiscal year, analysts forecast that the business will post sales of $1.51 billion per share, with estimates ranging from $1.50 billion to $1.53 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Qiagen N.V..
Qiagen N.V. (NASDAQ:QGEN) last released its quarterly earnings results on Monday, November 6th. The company reported $0.32 EPS for the quarter, hitting the consensus estimate of $0.32. Qiagen N.V. had a return on equity of 11.36% and a net margin of 6.40%. The firm had revenue of $364.00 million for the quarter, compared to analyst estimates of $363.42 million. During the same period in the previous year, the company posted $0.29 EPS. Qiagen N.V.’s revenue for the quarter was up 7.5% on a year-over-year basis.
Hedge funds have recently bought and sold shares of the stock. Acrospire Investment Management LLC raised its position in shares of Qiagen N.V. by 11.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 3,344 shares of the company’s stock valued at $112,000 after acquiring an additional 349 shares in the last quarter. Oppenheimer Asset Management Inc. raised its position in shares of Qiagen N.V. by 0.5% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 3,961 shares of the company’s stock valued at $133,000 after acquiring an additional 20 shares in the last quarter. Quadrant Capital Group LLC raised its position in shares of Qiagen N.V. by 4.1% during the 2nd quarter. Quadrant Capital Group LLC now owns 5,742 shares of the company’s stock valued at $183,000 after acquiring an additional 225 shares in the last quarter. Quantitative Systematic Strategies LLC acquired a new stake in shares of Qiagen N.V. during the 2nd quarter valued at approximately $211,000. Finally, Prudential Financial Inc. acquired a new stake in shares of Qiagen N.V. during the 1st quarter valued at approximately $207,000. 60.47% of the stock is currently owned by institutional investors and hedge funds.
Shares of Qiagen N.V. (NASDAQ QGEN) traded down $0.01 on Friday, hitting $31.02. The company’s stock had a trading volume of 727,960 shares, compared to its average volume of 1,289,319. Qiagen N.V. has a one year low of $27.51 and a one year high of $36.34. The firm has a market cap of $7,062.01, a price-to-earnings ratio of 25.22, a price-to-earnings-growth ratio of 1.90 and a beta of 1.13. The company has a debt-to-equity ratio of 0.68, a quick ratio of 4.78 and a current ratio of 5.33.
About Qiagen N.V.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with MarketBeat.com's FREE daily email newsletter.